	US 12,005,126 B2
	Compositions for oral administration of pentosan polysulfate in form of nanoparticles with improved intestinal absorption
Adolfo Gasparetto, Rome (IT); Fabio Borella, Rome (IT); Viviana Mascilongo, Rome (IT); Ruggero Bettini, Parma (IT); Fabio Sonvico, Parma (IT); and Marta Cito, Martina Franca (IT)
Assigned to ALMIRA PHARMA SRL, Rome (IT)
Appl. No. 17/255,603
Filed by NEXTRARESEARCH S.R.L., Rome (IT)
PCT Filed May 16, 2019, PCT No. PCT/EP2019/062662 § 371(c)(1), (2) Date Dec. 23, 2020, PCT Pub. No. WO2020/001852, PCT Pub. Date Jan. 2, 2020.
Claims priority of application No. 18180223 (EP), filed on Jun. 27, 2018.
Prior Publication US 2021/0260214 A1, Aug. 26, 2021
Int. Cl. A61K 31/737 (2006.01); A61K 9/00 (2006.01); A61K 47/61 (2017.01); A61K 47/69 (2017.01)

CPC A61K 47/6939 (2017.08) [A61K 9/0053 (2013.01); A61K 31/737 (2013.01); A61K 47/61 (2017.08); A61K 47/6943 (2017.08)]

3 Claims

1. An Oral Composition comprising nanoparticles of a complex of Pentosan Polysulfate sodium with chitosan, wherein the nanoparticles have a diameter between 80 and 220 nm and wherein the chitosan has a degree of deacetylation between 78 and 99% and molecular weight between 30 and 400 kDa.